/ibt.ams3.digitaloceanspaces.com%2FDNA-Sequencing.jpeg)
Investment Managers Blog
← Back to Investor Relations
Looking for the green shoots of recovery – the return of shareholder activism
How is AI transforming the biotechnology industry?
Is the looming ‘patent cliff’ more of a slope?
After six M&A deals for IBT in 2022, will 2023 be another bumper year for biotech M&A?
Biotech dealflow to heat up after turbulent 2022
Getting better at treating Alzheimer’s disease
Biotech and the impact of currency fluctuations
A review of IBT’s financial year
Biotech innovation continues apace despite market volatility
How to identify biotech diamonds in the rough
Six active approaches for a biotech boost
Biotech innovation will triumph over inflation
Global approach key to tapping biotech growth
Active vs passive investment amid a swinging biotech sector
Biotech – not a cyclical sector, but a cyclical investment environment
2021 - a year of two halves, optimistic for a recovery in 2022
Conditional drug approvals set to expand biotech universe
Further cancer breakthroughs hinge on biotech investment
M&A myth masks reality of biotech innovation
Pandemic provides launchpad for multi-year biotech boom
Biotech advances crucial in addressing ageing world
Gene editing breakthrough to power next biotech boom
Forget FAANGs – look to the US for the world’s best biotech
Innovation is the key not the culprit – IP waiving is counterproductive
Navigating the three-phase trial process of biotech companies
Meme, theme and the ARK Innovation momentum machine
What are rare diseases, and why are drug sales predicted to grow?
Themes for 2021
Vaccine arrives - at warp speed
How the Trust responds to macro-economic factors such as the U.S. election, Covid-19 and more
Acquisition premiums fuel interest in innovative biotech sector
Innovation continues to be a driver of performance within the biotech sector
COVID-19 vaccine, U.S. Presidential election and more
Trust’s NAV exceeds GBP 300 million
May ends with NAV at an all time high
Biotech’s long-term outlook remains strong amid COVID-19 volatility
Biopharma outperforms as it exhibits its defensive characteristics and plan of action against COVID-19
How International Biotechnology Trust has responded to COVID-19
The world wakes up to the reality of a pandemic
Fears rise that COVID-19 infection may escalate into a pandemic
2020 kicks off with the 38th Annual J.P. Morgan Healthcare Conference in San Francisco
Drug approvals and M&A drive strong month for biotech
Biotech sector ready for break-out after four years of consolidation
Rising earnings to pave the way for long-term outperformance
Investors Chronicle includes Trust in top 100 funds
In a world of trade wars and Brexit, the demand for healthcare remains intact